Edwards Lifesciences Corp (EW)

Return on assets (ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	4,174,600	4,158,900	1,473,000	1,413,800	1,402,400	1,430,900	1,389,500	1,488,800	1,521,900	1,458,800	1,455,400	1,538,500	1,503,100	1,477,300	1,462,400	851,000	823,400	794,100	743,600	1,107,800
Total assets	US$ in thousands	13,055,300	12,971,200	10,099,300	9,736,300	9,363,200	9,370,800	9,004,000	8,651,200	8,292,500	8,638,200	8,425,100	8,419,900	8,502,600	8,160,300	7,662,100	7,213,700	7,237,100	6,800,800	6,424,100	6,076,100
ROA		31.98%	32.06%	14.59%	14.52%	14.98%	15.27%	15.43%	17.21%	18.35%	16.89%	17.27%	18.27%	17.68%	18.10%	19.09%	11.80%	11.38%	11.68%	11.58%	18.23%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $4,174,600K ÷ $13,055,300K
= 31.98%

The return on assets (ROA) for Edwards Lifesciences Corp has shown some fluctuations over the periods provided. It stood at 18.23% on March 31, 2020, decreased to 11.58% by June 30, 2020, and then slightly increased to 11.68% by September 30, 2020. The ROA further declined to 11.38% by December 31, 2020.

However, there was a notable improvement in ROA during the first half of 2021, reaching 11.80% by March 31 and significantly increasing to 19.09% by June 30. The company maintained a relatively high ROA around 18% in the subsequent quarters of 2021 and the first half of 2022.

From March 31, 2022, to September 30, 2023, the ROA showed a decreasing trend, dropping from 18.27% to 15.27%. There was a slight uptick to 14.98% by December 31, 2023. The ROA continued to fluctuate around the mid-teens range in the first half of 2024.

A significant spike in ROA was observed in the third quarter of 2024, with the ROA reaching 32.06% on September 30, 2024, followed by a slightly lower but still strong ROA of 31.98% by December 31, 2024.

Overall, the ROA of Edwards Lifesciences Corp has exhibited variability but generally remained at healthy levels, showing periods of both increase and decrease. The company's ability to generate earnings from its assets has shown resilience, with some quarters demonstrating particularly strong performance. It would be important to monitor future ROA trends to assess the company's asset utilization and profitability efficiency.